Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221198 | 1.00 | SIRT2 (0.56) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL31243057 | 0.91 | CTSL (0.57) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL21221151 | 0.91 | FOLH1 (0.52) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL21232384 | 0.91 | FOLH1 (0.52) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL16441100 | 0.91 | FOLH1 (0.52) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL7362144 | 0.88 | SIRT2 (0.67) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL3624634 | 0.86 | FOLH1 (0.55) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL7286347 | 0.86 | FOLH1 (0.55) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL3624630 | 0.86 | FOLH1 (0.55) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL21232155 | 0.85 | CTSL (0.53) | SIRT2SIRT1SIRT3CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | STANDARD LLC | 2019-08-08 | — | — | US | disclosed |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | STANDARD LLC | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | MEF2D, MYLK2, TNNT2 | SIRT2 383/4885SIRT1 676/4885SIRT3 781/4885 |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | MEF2D, MYLK2, MYOF | SIRT2 447/4885SIRT1 605/4885SIRT3 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.